文献速递神经免疫

北美多发性硬化患者SARS-CoV-2感染结局与风险因素注册研究

Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis.
PubMed 文献 · JAMA Neurol · 2021-01-01

该注册研究纳入1626例北美多发性硬化合并SARS-CoV-2感染患者,发现总体死亡率为3.3%(95%CI 2.5%-4.3%)。校正其他风险因素后,行动障碍和年龄增长与各临床严重程度等级独立相关,非行动障碍者死亡OR达25.4。其他不良结局风险因素包括黑人种族、心血管合并症和近期使用皮质类固醇。

要点

  • 多发性硬化合并COVID-19患者总体死亡率为3.3%。
  • 非行动障碍者死亡风险显著升高(OR 25.4)。
  • 高龄、黑人种族、心血管合并症和近期皮质类固醇治疗与更差结局相关。

核心结论

  • 在多发性硬化患者中,行动障碍增加与包括死亡在内的COVID-19更差临床严重程度独立相关。
  • 其他不良结局风险因素包括年龄较大、黑人种族、心血管合并症和近期使用皮质类固醇。

研究设计与样本

  • 基于注册的横断面研究,使用2020年4月1日至12月12日北美学术和社区实践中医护人员报告的脱敏数据。
  • 纳入1626例多发性硬化合并SARS-CoV-2感染或高度疑似COVID-19患者。
  • 主要结局为4级临床严重程度:未住院、仅住院、入住ICU和/或需要呼吸机支持、死亡。

主要发现

  • 1626例患者中,82.7%(1345例)为实验室阳性SARS-CoV-2感染,74.0%(1202例)为女性,80.4%(1255例)为复发缓解型多发性硬化。
  • 61.5%(996例)为非西班牙裔白人,20.8%(337例)为黑人,11.7%(190例)为西班牙裔/拉丁裔;平均(SD)年龄47.7(13.2)岁,49.5%(797例)有1种或以上合并症。
  • 总体死亡率为3.3%(95%CI 2.5%-4.3%)。
  • 校正其他风险因素后,非行动障碍与仅住院(OR 2.8,95%CI 1.6-4.8)、入住ICU和/或需要呼吸机支持(OR 3.5,95%CI 1.6-7.8)、死亡(OR 25.4,95%CI 9.3-69.1)的 odds 增加独立相关。
  • 年龄每增加10岁与仅住院(OR 1.3,95%CI 1.1-1.6)、入住ICU和/或需要呼吸机支持(OR 1.3,95%CI 0.99-1.7)、死亡(OR 1.8,95%CI 1.2-2.6)的 odds 增加独立相关。

临床怎么用

  • 临床医生应识别具有行动障碍、高龄、黑人种族、心血管合并症或近期使用皮质类固醇的多发性硬化患者,这些患者可能需要更密集的监测或COVID-19治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Emergence of SARS-CoV-2 causing COVID-19 prompted the need to gather information on clinical outcomes and risk factors associated with morbidity and mortality in patients with multiple sclerosis (MS) and concomitant SARS-CoV-2 infections. OBJECTIVE: To examine outcomes and risk factors associated with COVID-19 clinical severity in a large, diverse cohort of North American patients with MS. DESIGN, SETTING, AND PARTICIPANTS: This analysis used deidentified, cross-sectional data on patients with MS and SARS-CoV-2 infection reported by health care professionals in North American academic and community practices between April 1, 2020, and December 12, 2020, in the COVID-19 Infections in MS Registry. Health care professionals were asked to report patients after a minimum of 7 days from initial symptom onset and after sufficient time had passed to observe the COVID-19 disease course through resolution of acute illness or death. Data collection began April 1, 2020, and is ongoing. EXPOSURES: Laboratory-positive SARS-CoV-2 infection or highly suspected COVID-19. MAIN OUTCOMES AND MEASURES: Clinical outcome with 4 levels of increasing severity: not hospitalized, hospitalization only, admission to the intensive care unit and/or required ventilator support, and death. RESULTS: Of 1626 patients, most had laboratory-positive SARS-CoV-2 infection (1345 [82.7%]), were female (1202 [74.0%]), and had relapsing-remitting MS (1255 [80.4%]). A total of 996 patients (61.5%) were non-Hispanic White, 337 (20.8%) were Black, and 190 (11.7%) were Hispanic/Latinx. The mean (SD) age was 47.7 (13.2) years, and 797 (49.5%) had 1 or more comorbidity. The overall mortality rate was 3.3% (95% CI, 2.5%-4.3%). Ambulatory disability and older age were each independently associated with increased odds of all clinical severity levels compared with those not hospitalized after adjusting for other risk factors (nonambulatory: hospitalization only, odds ratio [OR], 2.8 [95% CI, 1.6-4.8]; intensive care unit/required ventilator support, OR, 3.5 [95% CI, 1.6-7.8]; death, OR, 25.4 [95% CI, 9.3-69.1]; age [every 10 years]: hospitalization only, OR, 1.3 [95% CI, 1.1-1.6]; intensive care unit/required ventilator support, OR, 1.3 [95% CI, 0.99-1.7]; death, OR, 1.8 [95% CI, 1.2-2.6]). CONCLUSIONS AND RELEVANCE: In this registry-based cross-sectional study, increased disability was independently associated with worse clinical severity including death from COVID-19. Other risk factors for worse outcomes included older age, Black race, cardiovascular comorbidities, and recent treatment with corticosteroids. Knowledge of these risk factors may improve the treatment of patients with MS and COVID-19 by helping clinicians identify patients requiring more intense monitoring or COVID-19 treatment.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Salter A, Fox RJ, Newsome SD, et al. Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis. JAMA Neurol. 2021. PMID: 33739362. doi:10.1001/jamaneurol.2021.0688

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。